Association of the -14C/G MET and the -765G/C COX-2 gene polymorphisms with the risk of chronic rhinosinusitis with nasal polyps in a polish population

DNA and Cell Biology

Volumn 31, Issue 7, 2012, Pages 1258-1266

  Sitarek, Przemyslaw ^a   Zielinska Blizniewska, Hanna ^a   Dziki, Lukasz ^a   Milonski, Jaroslaw ^a   Przybylowska, Karolina ^a   Mucha, Bartosz ^a   Olszewski, Jurek ^a   Majsterek, Ireneusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; STEROID;

ADULT; AGED; ALLERGIC ASTHMA; ARTICLE; ASTHMA; CHRONIC RHINOSINUSITIS; CONTROLLED STUDY; CYCLOOXYGENASE 2 GENE; DNA ISOLATION; ETHNICITY; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MET GENE; NOSE POLYP; POLAND; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADULT; AGED; CHRONIC DISEASE; CYCLOOXYGENASE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; NASAL POLYPS; POLAND; POLYMORPHISM, SINGLE NUCLEOTIDE; SINUSITIS;

EID: 84863959312     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2011.1453     Document Type: Article

References (41)

1. Bachert, C., Van Zele, T., Gevaert, P., De Schrijver, L., and Van Cauwenberge, P. (2003). Superantigens and nasal polyps. Curr Allergy Asthma Rep 3, 523-531.
2. Balkovetz, D.F., and Lipschutz, J.H. (1999). Hepatocyte growth factor and the kidney: It is not just for the liver. Int Rev Cytol 186, 225-260.
3. Brosens, L.A., Iacobuzio-Donahue, C.A., Keller, J.J., Hustinx, S.R., Carvalho, R., Morsink, F.H., et al. (2005). Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G - > C COX-2 polymorphism. Clin Cancer Res 11, 4090-4096.
4. Brown, J.R., and DuBois, R.N. (2005). COX-2: A molecular target for colorectal cancer prevention. J Clin Oncol 23, 2840-2855.
5. Collins, J.G. (1997). Prevalence of selected chronic conditions: UNITED States, 1990-1992. Vital Health Stat 194, 1-89.
6. Coste, A., Brugel, L., and Maitre, B. (2000). Inflammatory cells as well as epithelial cells in nasal polyps express vascular endothelial growth factor. Eur Respir J 15, 367-372.
7. Coste, A., Wang, Q.P., and Roudot-Thoraval, F. (1996). Epithelial cell proliferation in nasal polyps could be upregulated by platelet-derived growth factor. Laryngoscope 106, 578-583.
8. Cowin, A.J., Kallincos, N., Hatzirodos, N., Robertson, J.G., Pickering, K.J., Couper, J., et al. (2001). Hepatocyte growth factor and macrophage-stimulating protein are upregulated during excisional wound repair in rats. Cell Tissue Res 306, 239-250.
9. Fernandez-Morata, J.C., Mullol, J., Fuentes, M., Pujols, L., Roca-Ferrer, J., Perez, M., et al. (2000). Regulation of cyclooxygenase-1 and - 2 expression in human nasal mucosa. Effects of cytokines and dexamethasone. Clin Exp Allergy 30, 1275-1284.
10. Fokkens, W., Lund, V., Bachert, C., Clement, P., Helllings, P., Holmstrom, M., et al. (2005). EAACI position paper on rhinosinusitis and nasal polyps executive summary. Allergy 60, 583-601.
11. Fritsche, E., Baek, S.J., King, L.M., Zeldin, D.C., Eling, T.E., and Bell, D.A. (2001). Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther 299, 468-476.
12. Gosepath, J., Brieger, J., Lehr, H.A., and Mann, W.J. (2005). Expression, localization, and significance of vascular permeability/vascular endothelial growth factor in nasal polyps. Am J Rhinol 19, 7-13.
13. Grimminger, P.P., Stohlmacher, J., Vallbohmer, D., Schneider, P.M., Holscher, A.H., Metzger, R., et al. (2009). Prognostic Significance and Clinicopathological Associations of COX-2 SNP in Patients with Nonsmall Cell Lung Cancer. J Oncol 2009, 139590.
14. Hamad, A.M., Sutcliffe, A.M., and Knox, A.J. (2004). Aspirininduced asthma: Clinical aspects, pathogenesis and management. Drugs 64, 2417-2432.
15. Hoff, J.H., te Morsche, R.H., Roelofs, H.M., Van Der Logt, E.M., Nagengast, F.M., and Peters, W.H. (2009). COX-2 polymorphisms - 765G- >C and - 1195A- >G and colorectal cancer risk. World J Gastroenterol 15, 4561-4565.
16. Horton, J.K., Williams, A.S., Smith-Phillips, Z., Martin, R.C., and O'Beirne G. (1999). Intracellular measurement of prostaglandin E2: Effect of anti-inflammatory drugs on cyclooxygenase activity and prostanoid expression. Anal Biochem 271, 18-28.
17. Huuskonen, K.H., Kunnas, T.A., Tanner, M.M., Mikkelsson, J., Ilveskoski, E., Karhunen, P.J., et al. (2008). COX-2 gene promoter polymorphism and coronary artery disease in middleaged men: The Helsinki sudden death study. Mediators Inflamm 2008, 289453.
18. Ishibashi, T., Tanaka, T., Nibu, K., Ishimoto, S., and Kaga, K. (1998). Keratinocyte growth factor and its receptor messenger RNA expression in nasal mucosa and nasal polyps. Ann Otol Rhinol Laryngol 107, 885-890.
19. Kristinsson, J.O., Van Westerveld, P., te Morsche, R.H., Roelofs, H.M.,Wobbes, T.,Witteman, B.J., et al. (2009). Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno- or squamous cell carcinoma. World J Gastroenterol 15, 3493-3497.
20. Langsenlehner, U., Yazdani-Biuki, B., Eder, T., Renner, W., Wascher, T.C., Paulweber, B., et al. (2006). The cyclooxygenase-2 (PTGS2) 8473T >C polymorphism is associated with breast cancer risk. Clin Cancer Res 12, 1392-1394.
21. Liu, Z., Kim, J., Sypek, J.P., Wang, I.M., Horton, H., Oppenheim, F.G., Bochner, B.S. (2004). Gene expression profiles in human nasal polyps tissues studied by means of DNA microarray. J Allergy Clin Immunol 114, 783-790.
22. Linton, M.F., and Fazio, S. (2004). Cyclooxygenase-2 and inflammation in atherosclerosis. Curr Opin Pharmacol 4, 116-123.
23. Mullol, J., Fernández-Morata, J.C., Roca-Ferrer, J., Pujols, L., Xaubet, A., Benitez, P., and Picado, C. (2002). Cyclooxygenase 1 and cyclooxygenase 2 expression is abnormally regulated in human nasal polyps. J Allergy Clin Immunol 109, 824-830.
24. Papafili, A., Hill, M.R., Brull, D.J., McAnulty, R.J., Marshall, R.P., Humphries, S.E., et al. (2002). Common promoter variant in cyclooxygenase-2 represses gene expression: Evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22, 1631-1636.
25. Peters, W.H., Lacko, M., Te Morsche, R.H., Voogd, A.C., Oude Ophuis, M.B., and Manni, J.J. (2009). COX-2 polymorphisms and the risk for head and neck cancer in white patients. Head Neck 31, 938-943.
26. Petruson, B., Hansson, H.A., and Petruson, K. (1988). Insulin-like growth factor I is a possible pathogenic mechanism in nasal polyps. Acta Otolaryngol 106, 156-160.
27. Puchelle, E. (2000) Airway epithelium wound repair and regeneration after injury. Acta Otorhinolaryngol Belg 54, 263-270.
28. Rho, H.S., Lee, S.H., Lee, H.M., Jung, H.H., Choi, J., Park, M.K., et al. (2006). Overexpression of hepatocyte growth factor and its receptor c-Met in nasal polyps. Arch Otolaryngol Head Neck Surg 132, 985-989.
29. Roca-Ferrer, J., Pujols, L., Gartner, S., Moreno, A., Pumarola, F., Mullol, J., et al. (2006). Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis. Thorax 61, 592-596.
30. Settipane, G.A., Lund,V.J, Bernstein, J.M, and Tos, M. (1997). Epidemiology of nasal polyps. In: NASAL Polyps: EPIDEMIOLOGY, Pathogenesis and Treatment. G.A. Settipane, V.J. Lund, J.M Bernstein, and M. Tos, eds. (OceanSide Publications, Inc., Providence, Rhode Island), pp. 17-24.
31. Shahedi, K., Lindstrom, S., Zheng, S.L., Wiklund, F., Adolfsson, J., Sun, J., et al. (2006). Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer 119, 668-672.
32. Shen, J., Gammon, M.D., Terry, M.B., Teitelbaum, S.L., Neugut, A.I., and Santella, R.M. (2006). Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res 8, R71.
33. Sitarz, R., Leguit, R.J., De Leng, W.W., Polak, M., Morsink, F.M., Bakker, O., et al. (2008). The COX-2 promoter polymorphism - 765 G>C is associated with early-onset, conventional and stump gastric cancers. Mod Pathol 21, 685-690.
34. Tan, W., Wu, J., Zhang, X., Guo, Y., Liu, J., Sun, T., et al. (2007). Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 28, 1197-1201.
35. Toyoda, M., Takayama, H., Horiguchi, N., Otsuka, T., Fukusato, T., Merlino, G., et al. (2001). Overexpression of hepatocyte growth factor/scatter factor promotes vascularization and granulation tissue formation in vivo. FEBS Lett 509, 95-100.
36. Vane, J.R., Bakhle, Y.S., and Botting, R.M. (1998). Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38, 97-120.
37. Weidner, K.M., Hartmann, G., Sachs, M., and Birchmeier, W. (1993). Properties and functions of scatter factor/hepatocyte growth factor and its receptor c-Met. Am J Respir Cell Mol Biol 8, 229-237.
38. Wilson, S.E., Liang, Q., and Kim, W.J. (1999). Lacrimal gland HGF, KGF, and EGF mRNA levels increase after corneal epithelial wounding. Invest Ophthalmol Vis Sci 40, 2185-2190.
39. Xing, L.L., Wang, Z.N., Jiang, L., Zhang, Y., Xu, Y.Y., Li, J., et al. (2008). Cyclooxygenase 2 polymorphism and colorectal cancer: - 765G>C variant modifies risk associated with smoking and body mass index. World J Gastroenterol 14, 1785-1789.
40. Yuan, A., Yu, C.J., Shun, C.T., Luh, K.T., Kuo, S.H., Lee, Y.C., et al. (2005). Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer 115, 545-555.
41. Zhang, X., Miao, X., Tan, W., Ning, B., Liu, Z., Hong, Y., et al. (2005). Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 129, 565-576.